Cite
HARVARD Citation
Martins, D. et al. (2019). Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. Pharmacoepidemiology and drug safety. 28 (5), pp. 726-733. [Online].